During the European League Against Rheumatism’s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, researchers presented findings on adalimumab biosimilars, referencing Humira.
During the European League Against Rheumatism’s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, researchers presented findings on adalimumab biosimilars, referencing Humira.
Potential adalimumab biosimilar demonstrates similar safety and immunogenicity to reference
In a multicenter, double-blind, parallel-group, 52-week phase 3 study,1 researchers compared the safety and efficacy of Fresenius Kabi’s proposed adalimumab biosimilar, MSB11022, with the originator product in patients with moderate-to-severe chronic plaque psoriasis.
The study included 443 patients from 69 sites that spanned 12 countries. Participants were randomized to receive either MSB11022 (n = 202) or the reference adalimumab (n = 189) at a dose of 80 mg subcutaneously on day 1, and 40 mg every other week from weeks 2 to 14. The primary endpoint of the study was Psoriasis Area and Severity Index (PASI) 75 at week 16.
Researchers presented interim results of the trial’s progression at 16 weeks during the conference. The study demonstrated that 89.6% of MSB11022 patients reached PASI 75, versus 91.5% of patients taking the originator product. The immunogenicity profiles were comparable.
Study finds trial dropouts do not affect determinations of clinical similarity
Amgen’s ABP 501, an EMA- and FDA-approved adalimumab biosimilar, was recently studied2 in a tipping point sensitivity analysis compared with reference adalimumab in the treatment of rheumatoid arthritis.
The study authors noted that patient withdrawals from trials can often lead to incomplete data collection and subsequent loss of statistical power of the trial. The goal of this study was to examine the potential effects of missing data and determine how sensitive the results are.
The primary endpoint of the study was measured by the American College of Rheumatology’s 20% improvement criteria (ACR20) at week 24. Among participants who completed the study, the ACR20 response rate was 77% for the biosimilar adalimumab group and 74.7% for the reference adalimumab group.
Researchers found that, overall, the tipping point sensitivity analyses demonstrated that the effects of missing data due to study dropouts would not change the overall conclusion of clinical similarity between the reference and the biosimilar products.
References
1. Hercogova J, Papp KA, Edwards CJ, et al. A randomized, double-blind trial comparing the efficacy, safety and immunogenicity of MSB11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis. Presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, June 13-16, 2018; Amsterdam, Netherlands. Abstract AB0954. doi: 10.1136/annrheumdis-2018-eular.5146.
2. Zhang N, Wang H, Krishnan E. Clinical equivalence in efficacy between ABP 501 and adalimumab in patients with moderate to severe rheumatoid arthritis: a tipping point analysis. Presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, June 13-16, 2018; Amsterdam, Netherlands. Abstract AB0457. doi: 10.1136/annrheumdis-2018-eular.6855.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.